Central Obesity, Time Restricted Eating
Conditions
Brief summary
Time-restricted eating (TRE) has gained attention as a promising dietary strategy for enhancing body composition and metabolic health. This innovative eating pattern involves confining daily food intake to a specific window, typically spanning 6-10 hours. Given the lack of consensus on the optimal TRE strategy, this research explores whether tailoring eating windows to individual chronotypes enhances TRE outcomes. This randomized controlled trial aims to evaluate the effects of chronotype-matched versus chronotype-unmatched TRE protocols, compared to a control group, over a 12-week period on visceral fat mass and other metabolic health outcomes in physically inactive adults with central obesity. Additionally, the study seeks to determine whether chronotype-matched TRE offers greater benefits in terms of visceral fat reduction and metabolic improvements compared to chronotype-unmatched TRE. Assessments will be conducted at baseline, and after the 12-week intervention.
Interventions
BEHAVIORALChronotype-matched time-restricted eating
A 12 weeks time-restricted eating intervention that match participants' chronotype
BEHAVIORALChronotype-unmatched time-restricted eating
A 12 weeks time-restricted eating intervention that not match participants' chronotype
Sponsors
Chinese University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Chinese adults, male or female, aged between 18-65 years old; 2. BMI of 23 kg/m² or higher, with a waist circumference exceeding 80 cm for females and 90 cm for males; 3. Weight stability for at least three months prior to the start of the study; 4. Physically inactive, indicated by not meeting established WHO guidelines on physical activity and sedentary behavior (i.e., at least 150-300 minutes of moderate-intensity or at least 75-150 minutes of vigorous-intensity aerobic exercise; or an equivalent combination of moderate and vigorous-intensity activity throughout the week; 5. Baseline eating duration exceeding 10 hours per day; 6. Identified as either early or late chronotypes (Morningness-Eveningness Questionnaire)
Exclusion criteria
1. Individuals currently or chronically receiving pharmacological treatment for hypertension, diabetes, weight loss, or other metabolic conditions; 2. Night shift workers; 3. Individuals with eating disorders; 4. Female participants who are breast-feeding, pregnant, or attempting to become pregnant; 5. Individuals currently participating in other weight-management programs or following other prescribed diet programs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visceral fat mass | 12 weeks | Visceral fat mass will be assessed using Magnetic Resonance Imaging (MRI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subcutaneous fat mass | 12 weeks | Subcutaneous fat mass will be assessed using Magnetic Resonance Imaging (MRI) |
| Body weight | 12 weeks | Body weight (kg) will be measured by a bioelectrical impedance analyzer (BIA) with minimum clothing. |
| Body mass index (BMI) | 12 weeks | BMI (kg/m2) will be calculated using body weight (kg) and height (m) |
| Body composition (Fat mass, fat free mass) | 12 weeks | Body composition including fat mass and fat-free mass (kg) will be measured by bioelectrical impedance analyzer (BIA) with minimum clothing. |
| Anthropometric measures | 12 weeks | Waist and hip circumferences (cm) will be assessed by standard procedures using a tension tape accurate to 0.1 cm. The waist-hip ratio will be calculated accordingly. |
| Fasting glucose metabolism | 12 weeks | Fasting blood samples will be used to analyze biomarkers of glucose metabolism, including fasting glucose (mmol/L), fasting insulin (mU/L), HbA1c (mmol/mol), as well as derived indices (HOMA-IR) calculated from fasting glucose and insulin levels. |
| Fasting lipid metabolism | 12 weeks | Fasting blood samples will be used to analyze different biomarkers of lipid metabolism including triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (mmol/L) |
| Dietary patterns | 12 weeks | Dietary pattern including eating window and dietary intake will be assessed using a seven-day food record |
| Subjective sleep quality | 12 weeks | Subjective sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI) |
| Objectively sleep quality | 12 weeks | Objectively sleep quality will be assessed by accelerometer |
| Subjective quality of life | 12 weeks | Quality of life will be assessed through questionnaires (WHOQOL-BREF) |
| Appetite | 12 weeks | Appetite will be measured by visual analog scale (VAS). |
Countries
China
Outcome results
None listed